143 related articles for article (PubMed ID: 11442492)
1. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
Braess J; Jahns-Streubel G; Schoch C; Haase D; Haferlach T; Fiegl M; Voss S; Kern W; Schleyer E; Hiddemann W
Br J Haematol; 2001 Jun; 113(4):975-82. PubMed ID: 11442492
[TBL] [Abstract][Full Text] [Related]
2. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
Br J Haematol; 2000 Jul; 110(1):170-9. PubMed ID: 10930995
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.
Jahns-Streubel G; Braess J; Schoch C; Fonatsch C; Haase D; Binder C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 2001 Mar; 15(3):377-84. PubMed ID: 11237060
[TBL] [Abstract][Full Text] [Related]
4. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Reuter C; Schleyer E; Rolf C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1997 Apr; 11(4):561-71. PubMed ID: 9096697
[TBL] [Abstract][Full Text] [Related]
6. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro.
Tosi P; Visani G; Ottaviani E; Testoni N; Pellacani A; Tura S
Eur J Haematol; 1998 Mar; 60(3):161-5. PubMed ID: 9548414
[TBL] [Abstract][Full Text] [Related]
7. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245
[TBL] [Abstract][Full Text] [Related]
8. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
[TBL] [Abstract][Full Text] [Related]
9. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
10. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Br J Haematol; 2001 Jan; 112(1):118-26. PubMed ID: 11167792
[TBL] [Abstract][Full Text] [Related]
11. No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
Visani G; Isidori A; Grafone T; Tosi P; Santini V; Malagola M; Martinelli G; Piccaluga PP; Gaziev D; Ottaviani E; Sparaventi G; Tura S
Leuk Lymphoma; 2004 Jul; 45(7):1361-4. PubMed ID: 15359633
[TBL] [Abstract][Full Text] [Related]
12. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
Löwenberg B; Suciu S; Archimbaud E; Ossenkoppele G; Verhoef GE; Vellenga E; Wijermans P; Berneman Z; Dekker AW; Stryckmans P; Schouten H; Jehn U; Muus P; Sonneveld P; Dardenne M; Zittoun R
Blood; 1997 Oct; 90(8):2952-61. PubMed ID: 9376575
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
[TBL] [Abstract][Full Text] [Related]
16. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
Jahns-Streubel G; Reuter C; Auf der Landwehr U; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Blood; 1997 Sep; 90(5):1968-76. PubMed ID: 9292531
[TBL] [Abstract][Full Text] [Related]
17. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
[TBL] [Abstract][Full Text] [Related]
19. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
20. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
